At Harley Street Fertility Clinic, we have always aspired to be at the forefront of reproductive medicine, offering our patients the most advanced and effective treatments available, with industry-leading medical care. This dedication to excellence is why we are particularly excited to share the ground-breaking findings from a recent comprehensive study published in the American Journal of Reproductive Immunology by our very own Consultant Dr George Ndukwe.
When the first Reproductive Immunology programme was established in the UK over 23 years ago, Dr George recalls that it was met with significant scepticism and controversy. The idea that immunological factors could play a critical role in reproductive success was revolutionary—and contentious. Yet, driven by a commitment to improve outcomes for women struggling with recurrent implantation failure (RIF) after assisted reproductive technology (ART), Dr George and his team persevered.
The study, led by the esteemed Professor Arri Coomarasamy and his dedicated team, has now validated the importance of immunomodulation in enhancing live birth rates (LBR) for women with RIF. Their exhaustive scrutiny of data from an impressive cohort of 27,163 women, of whom 5,083 received immunomodulation, provides compelling evidence for the efficacy of this approach.
Immunomodulation in this context involves the use of corticosteroids, low molecular weight heparin, and intravenous (IV) Intralipid. These treatments are administered after thorough immunological testing, including peripheral blood NK (natural killer) assay and TH1/TH2 intracellular cytokine ratios. By carefully modulating the immune system, these treatments aim to create a more favourable environment for embryo implantation and growth.
One of the most striking outcomes of the study is that the women who underwent immunomodulation were, on average, significantly older and had already experienced a higher number of failed ART cycles compared to those who did not. Despite these challenges, the women who received immunomodulation achieved a significantly higher LBR. Moreover, multivariate regression analysis confirmed that immunomodulation was a significant independent predictor of live birth.
These findings represent a monumental step forward in the field of reproductive medicine. For women who have faced the heartbreak of recurrent implantation failure, immunomodulation offers renewed hope and a significantly improved chance of achieving a successful pregnancy.
At Harley Street Fertility Clinic, under the expert eye of Dr George, we are immensely proud of the strides made in reproductive immunology and are committed to integrating these cutting-edge treatments into our practice. We believe that every patient deserves the best possible chance of success, and we are excited to offer immunomodulation with Dr George as a proven, effective option for those in need.
As we celebrate this milestone, we also look forward to continued advancements and innovations in reproductive medicine. Our ongoing collaboration with leading researchers and our commitment to evidence-based practice ensures that we remain at the cutting edge of fertility treatment, offering our patients the best possible care and outcomes.
In conclusion, the validation of immunomodulation as a significant predictor of live birth in women with RIF is not just a triumph of science but a beacon of hope for countless women and families. At Harley Street Fertility Clinic, we remain dedicated to transforming lives through pioneering treatments and compassionate care.
Book a consultation with Dr George here: https://hsfc.org.uk/contact